<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/AB7326B9-E2B0-4D96-A5AA-420917297B3C"><gtr:id>AB7326B9-E2B0-4D96-A5AA-420917297B3C</gtr:id><gtr:name>Charles River Laboratories</gtr:name><gtr:address><gtr:line1>Charles River Laboratories</gtr:line1><gtr:line2>Tranent</gtr:line2><gtr:postCode>EH33 2NE</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/75889A08-09F2-4189-90A5-97BB9647A023"><gtr:id>75889A08-09F2-4189-90A5-97BB9647A023</gtr:id><gtr:name>Argenta Discovery</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:department>School of Life Sciences</gtr:department><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AB7326B9-E2B0-4D96-A5AA-420917297B3C"><gtr:id>AB7326B9-E2B0-4D96-A5AA-420917297B3C</gtr:id><gtr:name>Charles River Laboratories</gtr:name><gtr:address><gtr:line1>Charles River Laboratories</gtr:line1><gtr:line2>Tranent</gtr:line2><gtr:postCode>EH33 2NE</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/75889A08-09F2-4189-90A5-97BB9647A023"><gtr:id>75889A08-09F2-4189-90A5-97BB9647A023</gtr:id><gtr:name>Argenta Discovery</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/EAC8A4C4-5D3E-4806-8BFE-20AED788D916"><gtr:id>EAC8A4C4-5D3E-4806-8BFE-20AED788D916</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Hayes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9534DA5F-B8C8-4006-A8B1-0B367F194856"><gtr:id>9534DA5F-B8C8-4006-A8B1-0B367F194856</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Brook</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0802629"><gtr:id>E6EA5E84-1FBF-4BFA-A725-F5D804C08FA3</gtr:id><gtr:title>The therapeutic potential of targeting RNA</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0802629</gtr:grantReference><gtr:abstractText>Myotonic Dystrophy (DM) is the most common form of muscular dystrophy in adults. Symptoms include muscle weakness and wasting, cataracts, diabetes, and irregular heartbeat. DM is an inherited condition that exists in two forms: DM1 and DM2. Both are caused by a different piece of faulty DNA. Recent experiments point to a common mechanism underlying both forms of DM. In both forms of DM the faulty DNA is made into RNA but this gets stuck in the nucleus and can be seen down the microscope as spots in the cells of DM patients. We have shown that three particular proteins, called muscleblind proteins, are present in the spots in DM cells. We aim to develop methods to study the faulty RNA, which will allow the development of assays or tests for drugs to treat the disorder. It is possible that the methods developed here may be applied to other human disorders.</gtr:abstractText><gtr:technicalSummary>Myotonic Dystrophy (DM) is the most common form of muscular dystrophy affecting adults. Symptoms include muscle weakness and wasting, myotonia, cardiac arrhythmias, diabetes, cataracts and premature balding in men. Two different mutations cause this condition. In 98 per cent of patients the disease is associated with a triplet repeat (CTG) expansion in the 3? untranslated region of the DMPK gene (DM1). In two percent the underlying mutation is a tetranucleotide (CCTG) expansion in an intron of the gene ZNF9 (DM2). In both cases the faulty gene is transcribed but the mutant RNA is trapped in the nuclei of DM cells, forming foci, which sequester muscleblind-like proteins. We propose a series of experiments to examine synthetic repeat-containing RNAs and in-vitro transcribed repeat expansion RNAs. We will produce the mutant RNAs and label them, and interacting molecules, using fluorophores to establish the methods to screen in vitro for compounds that may be useful as a therapy for DM. We hope to extend this work in the future to other mutant RNAs in human disease.</gtr:technicalSummary><gtr:fund><gtr:end>2010-09-16</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-09-17</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>87064</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Charles River Laboratories</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Drug development for myotonic dystrophy</gtr:description><gtr:id>70851AFA-7707-48E2-8777-C2418E728A86</gtr:id><gtr:impact>None yet, but patent filed</gtr:impact><gtr:partnerContribution>Medicinal Chemistry for drug development</gtr:partnerContribution><gtr:piContribution>Nuclear foci assay of DM cells</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Research and Development GSK</gtr:department><gtr:description>DM Therapy with GSK</gtr:description><gtr:id>018EB989-2CE6-4C32-B8B6-8EBF51401681</gtr:id><gtr:impact>None yet</gtr:impact><gtr:partnerContribution>A member of my lab worked at GSK for 3 months and they actioned a proteomics screen by Cellzome.</gtr:partnerContribution><gtr:piContribution>We have performed screens with reagents generated by GSK</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Cellzome Ltd</gtr:department><gtr:description>Kinome profiling with Cellzome</gtr:description><gtr:id>77A8AE61-708C-4AE0-BEFE-48B493BE57EE</gtr:id><gtr:impact>Paper submitted. Outcome pending</gtr:impact><gtr:partnerContribution>The Cellzome collaborators provide kinobead proteomic analysis.</gtr:partnerContribution><gtr:piContribution>We provided protein extracted from myotonic dystrophy patient cell lines</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Argenta Discovery</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Developing a drug to treat myotonic dystrophy</gtr:description><gtr:id>04A47E94-F7EF-450A-91D9-83872D705C13</gtr:id><gtr:impact>None yet</gtr:impact><gtr:partnerContribution>Argenta Discovery is a Med Chem company developing small molecules that we test.</gtr:partnerContribution><gtr:piContribution>We are trying to identify a drug to treat myotonic dystrophy in collaboration with Argenta Discovery. We have developed an assay which we are using to test compounds generated by Argenta.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MDSG AGM 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1F241D3C-A472-469A-A94E-A328562E3E87</gtr:id><gtr:impact>200 attendees, mostly patients and families with myotonic dystrophy but also some healthcare professionals.

Positive feedback from those present</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MDUK Meeting London 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>772D476E-6EA2-4D9E-933A-0B4BF59BC16D</gtr:id><gtr:impact>Workshop organized for muscular dystrophy patients</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MDSG Nottingham 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BEB5AA8A-9EF9-4A41-AFCC-8636AF87DFC8</gtr:id><gtr:impact>Informing a patient group about research progress</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MDSG Nottingham 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>961A24E4-54A8-4940-90DA-4729E9AD23FE</gtr:id><gtr:impact>Questions and subsequent discussion

Patients wanted to participate in research</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MDSG 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F57EDC9A-BCBF-4E5B-A3BD-7E22E892F98E</gtr:id><gtr:impact>The presentation to 200 patients and their families outlined research progress. I also ran 2 workshops on the same day, each attended by 30 - 50 people to provide further insight to research. The workshops lasted 1 hr and took the form of question and answer sessions.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>IDMC10 Paris 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2AAE6512-98BC-42B5-9F55-8B1F6E9CFAA1</gtr:id><gtr:impact>Presentation to lay group and professionals</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>IDMC9 San Sebastian, Spain 2013</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DCA90FDC-0C45-478A-BABF-6B0228A556A5</gtr:id><gtr:impact>The meeting was attended by 250 scientists working on DM.

Positive feedback from other scientists.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MDSG AGM Newcastle</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5B7F59F6-F421-41FC-86F3-EC0367A1856F</gtr:id><gtr:impact>Around 200 patients, carers and other family members affected by myotonic dystrophy attended

Patients have volunteered to participate in a National Register and for clinical trials</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>Pre-2006,2006,2007,2008,</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>3124782</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Seeding Drug Discovery</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>CA6BF5A8-84C9-4F5B-8B87-C5F98D67F93F</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>45000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leverhulme Research Fellowship</gtr:description><gtr:end>2012-03-02</gtr:end><gtr:fundingOrg>The Leverhulme Trust</gtr:fundingOrg><gtr:id>715B0658-D0D8-4106-B10B-7407E1356B51</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Multiple chemically modified oligonucleotides have been developed and tested in cell-based assays for their effectiveness. Progress has been achieved and this work is ongoing.</gtr:description><gtr:id>2E1F5F40-2E8B-432B-B1AF-1EBDEBEBB501</gtr:id><gtr:impact>No impacts to report, but we are only 12 months in to the project.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>chemically modified oligonucleotides</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/86F35F52-4336-47EF-B535-E4377C049EAA"><gtr:id>86F35F52-4336-47EF-B535-E4377C049EAA</gtr:id><gtr:title>High-content screening identifies small molecules that remove nuclear foci, affect MBNL distribution and CELF1 protein levels via a PKC-independent pathway in myotonic dystrophy cell lines.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/07a12283f0dab3df9ebfe8dbc12c7130"><gtr:id>07a12283f0dab3df9ebfe8dbc12c7130</gtr:id><gtr:otherNames>Ketley A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/291F6BB9-E2C5-4F55-AEF6-1EF2080B783B"><gtr:id>291F6BB9-E2C5-4F55-AEF6-1EF2080B783B</gtr:id><gtr:title>The miR-30 microRNA family targets smoothened to regulate hedgehog signalling in zebrafish early muscle development.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/07a12283f0dab3df9ebfe8dbc12c7130"><gtr:id>07a12283f0dab3df9ebfe8dbc12c7130</gtr:id><gtr:otherNames>Ketley A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/23189EBF-9F20-434B-8146-99929746519C"><gtr:id>23189EBF-9F20-434B-8146-99929746519C</gtr:id><gtr:title>Zebrafish deficient for Muscleblind-like 2 exhibit features of myotonic dystrophy.</gtr:title><gtr:parentPublicationTitle>Disease models &amp; mechanisms</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3ca69782e033b473bfc42ce1dc5bccd2"><gtr:id>3ca69782e033b473bfc42ce1dc5bccd2</gtr:id><gtr:otherNames>Machuca-Tzili LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1754-8403</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C319EA7D-DE01-46E3-BAEF-AC144EC4561A"><gtr:id>C319EA7D-DE01-46E3-BAEF-AC144EC4561A</gtr:id><gtr:title>Expanded CUG repeats Dysregulate RNA splicing by altering the stoichiometry of the muscleblind 1 complex.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a95aa498ef1e03c2cdf6b5e16f600c96"><gtr:id>a95aa498ef1e03c2cdf6b5e16f600c96</gtr:id><gtr:otherNames>Paul S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0802629</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>